GlassScriptPhysician profile
Julia Lace Short
NPI 1316510027
$919.33
in general payments reported to CMS, 2019-2025
12 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.17 · 2022: $152 · 2023: $269 · 2024: $260 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $217.46 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $167.87 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $158.02 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $85.12 | 2023-2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $75.20 | 2024 | Keveyis |
| Biogen, INC. | $58.97 | 2025 | Skyclarys |
| Cardiovascular Systems INC. | $49.17 | 2021 | |
| Exact Sciences Corporation | $36.60 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $22.88 | 2023 | |
| Glaxosmithkline, LLC. | $18.64 | 2024 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $15.69 | 2025 | Voquezna |
| Amgen INC. | $13.71 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.